Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-DUALNK
- Development stage
- Phase 2
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EB-DUALNK is an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Beijing Biotech (Biotech Pharmaceutical). It is designed for the treatment of recurrent or refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The therapy involves engineering natural killer cells to express CARs that simultaneously target two tumor-associated antigens, which may include GD2, MUC1, PSMA, or mesothelin. This dual-targeting approach is intended to enhance tumor recognition and mitigate antigen escape, a common mechanism of resistance in single-target cell therapies. The clinical program involves a Phase 1/2 study evaluating safety and preliminary efficacy following lymphodepleting chemotherapy.
- Other names
- Dual-targeting CAR-NK cellsMSLN/FOLR1/MUC16 CAR-NK cellsDual-target chimeric antigen receptor natural killer cells
02
Targets
MesothelinMUC1 (Mucin-1 Antigen)PSMA (Prostate-specific membrane antigen)GD2
Beyond the preview
Go deeper on EB-DUALNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-DUALNK.